期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

替吉奥联合奥沙利铂治疗老年晚期大肠癌的临床观察 被引量：11

暂未订购
导出
摘要 目的:观察替吉奥联合奥沙利铂治疗老年晚期大肠癌的近期疗效和不良反应。方法:42例老年晚期大肠癌患者(年龄≥65岁)口服替吉奥40～60mg/次,每天2次,第1～14天;奥沙利铂100mg/m2,第1天。21d为1个周期,至少治疗2个周期,评价疗效和毒副作用。结果:42例患者有效率为45.2%,临床受益率81.0%。主要不良反应为血液学毒性、胃肠道反应、外周神经毒性和口腔黏膜炎。结论:替吉奥联合奥沙利铂治疗老年晚期大肠癌近期疗效好,毒副反应小,耐受性好,可明显提高患者生活质量,值得在临床应用。
作者 郭守俊 康昭洵 曾红学
机构地区 江西省赣州市肿瘤医院
出处 《实用医学杂志》 CAS 北大核心 2012年第23期3999-4000,共2页 The Journal of Practical Medicine
关键词 结直肠肿瘤 替吉奥 奥沙利铂 化疗
分类号 R735.34 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1孙燕,管忠震,金懋林,李维廉,李丽庆,石廷章,周立中,隋广杰,许立功,宋恕平,许德凤,李容,李扬,黄富麟,张嘉庆,张和平,Brienza S,鞠利雅.奥沙利铂单药或与氟尿嘧啶-甲酰四氢叶酸联合应用治疗晚期大肠癌Ⅱ期临床试用报告[J].癌症,1999,18(3):237-240. 被引量：347
  • 2Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S- 1 ) : a review [ J ]. The Oncologist, 2002,7 : 288-323.
  • 3Tanaka F, Fukuse T, Wada H, et al. The history,mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agants [J]. Curr Pharm Biotechnol, 2000,1(2):137-164.
  • 4朱仲玲,薛津怀,阎昭,朱莉,刘美君.肿瘤患者单次和多次口服替吉奥片的药动学研究[J].中国肿瘤临床,2011,38(10):594-597. 被引量：10
  • 5Koizumi W, kurihara M, Nakano S, et al. Phase II study of S-1,a novel oral derivative of 5-fluorouracil,in advanced gastric cancer [J]. Oncology, 2000,58(3):191-197.
  • 6Ohtsu A, Baba H, Sakta Y, et al. Phase II study of S-1,a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma : for the S- 1 Cooperative Colorectal Carcinoma Study Group [J]. Brit J Canc, 2000,83 (2) : 141-145.
  • 7Zang D Y, Lee B H, Park H C, et al. Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer [ J ]. Annals of Oncologe, 2009.20 ( 5 ) : 892-896.
  • 8蒲东升.奥沙利铂联合卡培他滨治疗中老年晚期结肠癌的临床观察[J].中国老年学杂志,2011,31(9):1673-1674. 被引量：28
  • 9Porschen R, Arkenau H T, Kubicka S, et al. Phase III study of capecitabine plus oxaliplation compared with fluouracil and leueovorin plus oxaliplation in metastatic colorectal cancer:a final report of the AIO Colorectal Study Group [J]. J Clin Oncol, 2007,25 (27) : 4217-4223.

二级参考文献20

  • 1李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量：868
  • 2Sakamoto J, Clin K, Kondo K, et al. Phase I1 study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer [J].Anticancer Drugs,2006;17 (2): 231-6.
  • 3Hong YS, Song SY, Lee SI, et al. A phase II trail of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer [J].Ann Oncol, 2004;15(9) : 1344-7.
  • 4Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients [J]. Cancer Chemother Pharmacol, 2000:45(4) :291-7.
  • 5Sileri P, Dugo S, Bennavoli D,et al. Metachronous splenicmetastasis from colonic carcinoma five years after surgery : a case report and literature review[ J]. South Med J ,2009 ; 102 (7) :733-5.
  • 6Kweekel DM. Antonini NF. Nortier JW, et al. Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array[ J]. Br J Cancer, 2009;101(2) :357-62.
  • 7Shirasaka T,Nakano K,Takechi T,et al.Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats[J].Cancer Res,1996,56(11):2602-2606.
  • 8Hirata K,Horikoshi N,Aiba K,et al.Pharmacokinetic study of S-1,a novel oral fluorouracil antitumor drug[J].Clin Cancer Res,1999,5(8):2000-2005.
  • 9Shirasaka T.Development history and concept of an oral anticancer agent S-1 (TS-1):its clinical usefulness and future vistas[J].Jpn J Clin Oncol,2009,39(1):2-15.
  • 10Saif MW,Syrigos KN,Katirtzoglou NA.S-1:a promising new oral fluoropyrimidine derivative[J].Expert Opin Investig Drugs,2009,18(3):335-348.

共引文献382

同被引文献92

  • 1沈琳,马冬.晚期结直肠癌使用FOLFOX4或奥沙利铂断断-续续模式的FOLFOX7(OPTIMOX1)的随机临床研究[J].循证医学,2006,6(5):259-262. 被引量：47
  • 2孙燕,周际昌.临床肿瘤内科手册[M].3版.北京:人民卫生出版社,1998:24-54.
  • 3Gilles Manceau,Mehdi Karoui,Andrew Werner,Neil J Mortensen,Laurent Hannoun.Comparative outcomes of rectal cancer surgery between elderly and non-elderly patients: a systematic review[J].Lancet Oncology.2012(12)
  • 4Geerard L Beets,Regina GH Beets-Tan.Capecitabine in the treatment of rectal cancer[J].Lancet Oncology.2012(6)
  • 5Carlos Fernández-Martos,Miquel Nogué,Paloma Cejas,Víctor Moreno-García,Ana Hernández Machancoses,Jaime Feliu.The Role of Capecitabine in Locally Advanced Rectal Cancer Treatment[J].Drugs.2012(8)
  • 6Koh Miura,Tetsuhiko Shirasaka,Hiroki Yamaue,Iwao Sasaki.S-1 as a core anticancer fluoropyrimidine agent[J].Expert Opinion on Drug Delivery.2012(3)
  • 7Robert Glynne-Jones,Miranda Kronfli.Locally Advanced Rectal Cancer: A Comparison of Management Strategies[].Drugs.2011
  • 8Illum Henrik.Current status of radiosensitizing agents for the management of rectal cancer[].Critical reviews in oncogenesis.2012
  • 9Tanis PJ,Doeksen A,van Lanschot JJ.Intentionally curative treatment of locally recurrent rectal cancer:a systematic review[].Canadian journal of Surgery.2013
  • 10Sadahiro S,Suzuki T,Tanaka A,Okada K,Kamijo A,Murayama C,Akiba T,Nakayama Y.Phase I/II study of preoperative concurrent chemoradiotherapy with S-1 for locally advanced,resectable rectal adenocarcinoma[].Oncology.2011

引证文献11

二级引证文献32

实用医学杂志
2012年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部